Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 Now Available at iData Insights Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015 , provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the 1
focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173354/chronicmyelocytic-leukemia-cml-chronic-myeloid-leukemia-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173354/chronic-myelocytic-leukemia-cml-chronic-myeloid-leukemia-pipeline-review-h22015 Table of Contents
Introduction 10 Global Markets Direct Report Coverage 10 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Overview 11 Therapeutics Development 12 Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 12 Pipeline Products for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Comparative Analysis 13 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Development by Companies 14 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics under Investigation by Universities/Institutes 19 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Development by Companies 25
2
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Products under Investigation by Universities/Institutes 30 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 32 Altor BioScience Corporation 32 Aprea AB 33 arGEN-X BV 34 Ariad Pharmaceuticals, Inc. 35 Array BioPharma Inc. 36 Astex Pharmaceuticals, Inc. 37 Baxalta Incorporated 38 Bellicum Pharmaceuticals, Inc. 39 Bio-Path Holdings, Inc. 40 Biogenomics Limited 41 BioLineRx, Ltd. 42 BioSight Ltd. 43 Boston Biomedical, Inc. 44 Bristol-Myers Squibb Company 45 Cantargia AB 46 Celgene Corporation 47 Constellation Pharmaceuticals, Inc. 48 Daiichi Sankyo Company, Limited 49 Deciphera Pharmaceuticals, LLC 50 Eisai Co., Ltd. 51 EpiZyme, Inc. 52 Galena Biopharma, Inc. 53 Gamida Cell Ltd. 54 HEC Pharm Co., Ltd. 55 3
Hybrigenics S.A. 56 Ilyang Pharmaceutical Co., Ltd 57 Incyte Corporation 58 Jiangsu Hansoh Pharmaceutical Co., Ltd. 59 Juno Therapeutics Inc. 60 JW Pharmaceutical Corporation 61 KaloBios Pharmaceuticals, Inc. 62 Karyopharm Therapeutics, Inc. 63 Lixte Biotechnology Holdings, Inc. 64 Millennium Pharmaceuticals, Inc. 65 Mirna Therapeutics, Inc. 66 Natco Pharma Limited 67 Novartis AG 68 Onconova Therapeutics, Inc. 69 Ono Pharmaceutical Co., Ltd. 70 Oribase Pharma 71 Pfizer Inc. 72 Pharma Mar, S.A. 73 PharmaEssentia Corporation 74 Selvita SA 75 Shenogen Pharma Group Ltd. 76 Stemline Therapeutics, Inc. 77 Sun Pharma Advanced Research Company Ltd. 78 Targazyme, Inc. 79 Teva Pharmaceutical Industries Limited 80 Threshold Pharmaceuticals, Inc. 81
4
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Combination Products 83 Assessment by Target 84 Assessment by Mechanism of Action 89 Assessment by Route of Administration 93 Assessment by Molecule Type 95 Drug Profiles 97 (camptothecin + podofilox) - Drug Profile 97 ABL-001 - Drug Profile 98 AIC-47 - Drug Profile 99 ALT-803 - Drug Profile 100 anagrelide hydrochloride CR - Drug Profile 103 APR-246 - Drug Profile 104 ARGX-110 - Drug Profile 106 azacitidine - Drug Profile 109 binimetinib - Drug Profile 113 BL-8040 - Drug Profile 118 BMS-833923 - Drug Profile 120 bosutinib - Drug Profile 122 BP-100101 - Drug Profile 125 BPX-501 - Drug Profile 127 BST-236 - Drug Profile 129 CAN-04 - Drug Profile 130 Cell Therapy to Target GM-CSF for Oncology - Drug Profile 132 Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 134 CPI-0610 - Drug Profile 135 5
CT-413 - Drug Profile 136 CWP-291 - Drug Profile 137 D-12PGJ3 - Drug Profile 139 D-824 - Drug Profile 140 danusertib - Drug Profile 141 Dendritic Cell Therapy for Chronic Myeloid Leukemia - Drug Profile 143 Dendritic Cell Therapy for Hematological Malignancies - Drug Profile 144 Dendritic Cell Therapy for Oncology - Drug Profile 145 Dendritic Cell Therapy for Oncology and Infectious Disease - Drug Profile 146 Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 147 DS-3032 - Drug Profile 148 E-6201 - Drug Profile 149 erismodegib - Drug Profile 151 ETC-027 - Drug Profile 154 ETC-219 - Drug Profile 155 evofosfamide - Drug Profile 156 flumatinib mesylate - Drug Profile 164 Gene Therapy for Oncology - Drug Profile 165 guadecitabine - Drug Profile 166 Hu8F4 - Drug Profile 170 inecalcitol - Drug Profile 171 inotuzumab ozogamicin - Drug Profile 174 interferon alfa-2a - Drug Profile 176 interferon alfa-2b - Drug Profile 177 ipilimumab - Drug Profile 178 ixazomib citrate - Drug Profile 183
6
JTCR-016 - Drug Profile 187 KB-004 - Drug Profile 188 LB-100 - Drug Profile 190 LB-102 - Drug Profile 192 lirilumab - Drug Profile 194 lurbinectedin - Drug Profile 196 MJ-05 - Drug Profile 199 MRX-102 - Drug Profile 200 MRX-34 - Drug Profile 202 napabucasin - Drug Profile 204 NiCord - Drug Profile 207 nivolumab - Drug Profile 208 NOV-120501 - Drug Profile 216 NRCAN-019 - Drug Profile 217 omacetaxine mepesuccinate - Drug Profile 219 ORB-0001 - Drug Profile 222 pegaspargase - Drug Profile 223 PF-114 - Drug Profile 225 pinometostat - Drug Profile 226 ponatinib hydrochloride - Drug Profile 229 PRI-724 - Drug Profile 232 radotinib - Drug Profile 234 rebastinib tosylate - Drug Profile 236 rigosertib sodium - Drug Profile 238 ropeginterferon alfa-2b - Drug Profile 243 ruxolitinib phosphate - Drug Profile 246 SEL-24B489 - Drug Profile 251 7
selinexor - Drug Profile 252 SL-401 - Drug Profile 258 SL-501 - Drug Profile 260 Small Molecule to Inhibit ADAR1 for Chronic Myeloid Leukemia - Drug Profile 261 Small Molecules to Inhibit Abl Tyrosine Kinase for CML - Drug Profile 262 Small Molecules to Inhibit BCR-ABL for CML - Drug Profile 263 Small Molecules to Inhibit Bcr-Abl for CML and Pancreatic Cancer - Drug Profile 264 Small Molecules to Inhibit BRCA2/Rad51 Interaction for Cancer - Drug Profile 265 SNG-1153 - Drug Profile 266 SNG-162 - Drug Profile 267 SUNK-706 - Drug Profile 269 TR-120 - Drug Profile 270 trametinib dimethyl sulfoxide - Drug Profile 271 TZ-101 - Drug Profile 274 Vaccine to Target Bcr-Abl Tyrosine Kinase for Chronic Myeloid Leukemia - Drug Profile 276 Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile 277 Vaccine to Target WT1 for CML and AML - Drug Profile 278 Vaccine to Target WT1 for Oncology - Drug Profile 279 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Recent Pipeline Updates 280 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 414 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 420 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 422 Featured News & Press Releases 422 Appendix 433 Methodology 433 Coverage 433
8
Secondary Research 433 Primary Research 433 Expert Panel Validation 433 Contact Us 433 Disclaimer 434"
Read More http://www.idatainsights.com/reports-landing-page.php?id=173354/chronicmyelocytic-leukemia-cml-chronic-myeloid-leukemia-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
9